The Patent Finder

ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy

Shire LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2016/026352, filed Apr 7, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,787,515ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy
In force
 · High confidence
Takeda Pharmaceutical Company LimitedIn force
High confidence
US 12,435,146ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy
In force
 · High confidence
Shire Human Genetic Therapies, Inc.In force
High confidence
Application 16/991,762ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy
Abandoned
Abandoned Apr 26, 2023
Takeda Pharmaceutical Company LimitedAbandonedAbandoned Apr 26, 2023
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Shire LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited